Re the article: 'Impact of the boost dose of 10Gy versus 26Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. On behalf of the EORTC Radiation Oncology and Breast Cancer Groups. Radiother Oncol 2009;90:80-5'.

摘要

Dr. Poortmans and his colleagues need to be complimented for conducting and reporting the EORTC 22881-10882 "boost" trial [1 ]. This trial addresses a very relevant issue for the breast radiation oncologists. It investigates the relevance of a boost dose to the primary tumour site after lumpectomy and whole breast irradiation. Intuitively it can be stated that higher doses should lead to significantly better local control rates. In this context, the results of the trial are provocative indeed.